Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

Recruiting now

Conditions studied: Serum Uric Acid

In brief

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Key facts

Study ID

NCT07091526

Run by

Hepatopancreatobiliary Surgery Institute of Gansu Province

People needed

168

Starts

2025-07-29

Expected to finish

2026-12-29

Last updated by the study team

2025-12-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with pathologically confirmed pancreatic cancer (primary)
• Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
• The postoperative survival time was at least 6 weeks

You may not qualify if…

• No surgery was performed, or only palliative surgery/ biopsy was performed
• Patients who underwent emergency hemodialysis or plasma exchange after surgery
• History of gout or long-term urate-lowering therapy, such as allopurinol
• Patients are missing follow-up data
• Hydrochlorothiazide and furosemide were used
• Chronic kidney disease
• Oncolytic syndrome
• Hemolytic anemia
• Lead poisoning
• Hyperparathyroidism
• Hypothyroidism
• A tyrosinase inhibitor was used
• Patients with nonpancreatic primary tumors
• Pregnant or postpartum women.

Where it is running

• Hepatopancreatobiliary Surgery Institute of Gansu Province — Lanzhou, Gansu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.